Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 8, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 10, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001093557-26-000045
Filed / recorded
Mar 10, 2026, 8:01 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
DEXCOM INC
Issuer CIK
1093557
Ticker
DXCM
Reporting person
Jon Coleman
Relationship
Officer
Officer title
EVP, Chief Commercial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 8, 2026
Transaction code
A
Shares / units
43,897
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
112,635
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.
Included in this number are 112,635 unvested RSUs, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 68,738 of which were granted on May 22, 2025 and shall vest through May 22, 2029.